During its session at the 44th Annual J.P. Morgan Healthcare Conference, ANI Pharmaceuticals’ leadership underscored the company’s shift from a traditional generics provider to a high-growth rare disease specialist. CEO Nikhil Lalwani and CFO Steve Carey highlighted projections for 2026 revenue exceeding $1 billion, a 26% increase over 2025, driven by ramping sales of their lead rare disease asset, purified Cortrophin Gel. They noted that the rare disease portfolio will represent approximately 60% of total revenues by 2026, supported by investments funded from strong cash flows generated by their generics and branded products business.

ANI closed 2025 with better-than-expected performance, delivering over 39% year-over-year revenue growth on the strength of both niche branded products and its U.S. manufacturing-backed generics pipeline. For fiscal 2026, management issued guidance of $1.055–$1.115 billion in revenues, reflecting approximately 60% top-line growth compared to 2025. This bullish outlook incorporates contributions from recently launched rare disease therapies as well as continued expansion in existing generic markets.

Purified Cortrophin Gel remains ANI’s primary growth engine, with projected sales of $540–$575 million in 2026. Management detailed plans to add 90 sales representatives to support broader prescribing in endocrinology and nephrology specialties. A pivotal Phase 4 trial designed to expand the product’s label and secure long-term reimbursement is expected to commence in the second half of 2026, aiming to underpin multiyear durability of Cortrophin Gel revenues.

At current valuation levels, ANI trades at approximately 11.2x forward P/E, representing a 43% discount to the broader small-cap healthcare sector. The company ended the year with $285 million in unrestricted cash and maintains zero net debt burn expectations for 2026. This liquidity cushion supports ongoing R&D investments and potential strategic acquisitions to further enhance its rare disease pipeline.